Key Takeaways
- • Morgan Stanley identifies a $70 billion Alzheimer's drug market opportunity, subdivided between cognitive decline therapies and symptom management treatments, with healthcare value extending beyond drugmakers to diagnostics, care delivery, insurance, and retirement sectors.
- • In-vivo gene editing represents a $10 billion market opportunity by 2035 according to Morgan Stanley forecasts—significantly above consensus estimates of $6 billion—with critical data readouts expected over the next 18 months that will shape investor valuations of these platforms.
- • Morgan Stanley favors AI infrastructure suppliers (data, tools, and computing providers) over AI-dependent drug developers, citing potential to reduce discovery timelines from 4.5 years to 1.5 years and cut R&D costs by 25% to 60%, though clinical efficacy gains remain unproven.
- • The bank's analysis, presented by analysts Sean Laaman and Maxwell Skor at Morgan Stanley's annual Global Healthcare Conference, positions early-stage clinical data as a key inflection point for biotech valuation across all three sectors through 2027.
Summary
Morgan Stanley has identified three biotech breakthroughs as meaningful investment opportunities, spanning Alzheimer's therapeutics, in-vivo gene editing, and AI-driven drug discovery. The research, conducted by analysts Sean Laaman and Maxwell Skor and presented at the bank's Global Healthcare Conference in New York, offers a framework for institutional investors to assess high-risk, high-reward positions in emerging biotech subsectors.
The Alzheimer's drug market represents the largest near-term opportunity, valued at $70 billion by Morgan Stanley. The bank segments this market into two distinct categories: therapies that slow cognitive decline and treatments targeting behavioral symptoms such as psychosis and agitation. Critically, Morgan Stanley identifies value creation extending well beyond pharmaceutical manufacturers. By delaying nursing home entry by 12 to 18 months, the healthcare system could realize value worth multiples of drug list prices. This dynamic creates secondary investment opportunities for diagnostic firms, care delivery providers, retirement operators, and insurance companies—entities that may benefit from or require adaptation to shifting patient treatment paradigms.
In-vivo gene editing technologies present a second major opportunity. Unlike earlier ex-vivo approaches requiring cell extraction, laboratory editing, and reinfusion, in-vivo therapies edit DNA directly within the body. This capability unlocks previously inaccessible organs including the brain, heart, eyes, and liver. Morgan Stanley forecasts an in-vivo gene-editing market of $10 billion by 2035, substantially above the current consensus estimate of $6 billion. The bank emphasizes that clinical data due over the next 18 months will be determinative for platform valuations, indicating significant near-term volatility and inflection points for investors.
Regarding artificial intelligence applications, Morgan Stanley projects transformative efficiency gains: discovery timelines could compress from approximately 4.5 years to 1.5 years, while R&D cost reductions of 25% to 60% are achievable. However, the bank notes a critical limitation: minimal evidence demonstrates that AI increases the probability of drug approval and patient access. Consequently, Morgan Stanley favors "picks and shovels" plays—suppliers of data, computational tools, and infrastructure—over biotech firms dependent on AI for clinical success. These infrastructure providers already monetize adoption and face lower risk from binary clinical trial outcomes. The bank selectively monitors AI-native biotechs for clinical milestones while treating large-cap pharmaceutical productivity claims with skepticism.
The Alzheimer's drug market represents the largest near-term opportunity, valued at $70 billion by Morgan Stanley. The bank segments this market into two distinct categories: therapies that slow cognitive decline and treatments targeting behavioral symptoms such as psychosis and agitation. Critically, Morgan Stanley identifies value creation extending well beyond pharmaceutical manufacturers. By delaying nursing home entry by 12 to 18 months, the healthcare system could realize value worth multiples of drug list prices. This dynamic creates secondary investment opportunities for diagnostic firms, care delivery providers, retirement operators, and insurance companies—entities that may benefit from or require adaptation to shifting patient treatment paradigms.
In-vivo gene editing technologies present a second major opportunity. Unlike earlier ex-vivo approaches requiring cell extraction, laboratory editing, and reinfusion, in-vivo therapies edit DNA directly within the body. This capability unlocks previously inaccessible organs including the brain, heart, eyes, and liver. Morgan Stanley forecasts an in-vivo gene-editing market of $10 billion by 2035, substantially above the current consensus estimate of $6 billion. The bank emphasizes that clinical data due over the next 18 months will be determinative for platform valuations, indicating significant near-term volatility and inflection points for investors.
Regarding artificial intelligence applications, Morgan Stanley projects transformative efficiency gains: discovery timelines could compress from approximately 4.5 years to 1.5 years, while R&D cost reductions of 25% to 60% are achievable. However, the bank notes a critical limitation: minimal evidence demonstrates that AI increases the probability of drug approval and patient access. Consequently, Morgan Stanley favors "picks and shovels" plays—suppliers of data, computational tools, and infrastructure—over biotech firms dependent on AI for clinical success. These infrastructure providers already monetize adoption and face lower risk from binary clinical trial outcomes. The bank selectively monitors AI-native biotechs for clinical milestones while treating large-cap pharmaceutical productivity claims with skepticism.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.